High hopes and high costs: Exploring advances in Duchenne muscular dystrophy gene therapy

To help neurologists, clinicians and families understand the current evidence for a new gene therapy for Duchenne muscular dystrophy called delandistrogene moxeparvovec, the American Academy of Neurology (AAN) has issued an Evidence in Focus article in Neurology.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup